Cellusion selected for METI’s “J-Startup” support program


Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”) announced that the company has been selected for “J-Startup,” a startup support program promoted by the Ministry of Economy, Trade and Industry (METI) in the public and private sectors.

With support from J-Startup, Cellusion will accelerate to deliver novel regenerative therapy for all bullous keratopathy patients.

[About J-Startup]
The J-Startup project aims to make winning startups in the global market and bring new value to the world. It will also create successful, cutting-edge Japanese startups and empower Japan’s startup ecosystem.
For more information, please visit the website.

[About Cellusion]
Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi endothelial cells. Cellusion’s mission is “Regenerating Human Potential,” and its vision is “More Freedom and More Smiles to the World.”

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN
Founded: January 2015

For further information: please ask us through the contact form on our website.

Back to the List